SCHEMBL18330481

SCHEMBL18330481

CCOCC(=O)NC1CCN(CC)CC1

nearest known ligand 0.49

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 4/20 0.49
KDM4E B2RXH2 3/20 0.47
MEN1 O00255 1/20 0.47
MAPT P10636 1/20 0.47
KMT2A Q03164 1/20 0.47
EPHX1 P07099 1/20 0.47
EPHX2 P34913 1/20 0.47
USP2 O75604 2/20 0.46
RECQL P46063 1/20 0.45
NPSR1 Q6W5P4 2/20 0.44
POLB P06746 1/20 0.43
GAA P10253 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
DRD2 P14416 1/20 0.41
HTR2A P28223 1/20 0.41
DRD3 P35462 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5316785 0.85 NPSR1 (0.62) L3MBTL1KDM4EMEN1MAPTKMT2A
SCHEMBL18330454 0.85 USP2 (0.47) L3MBTL1KDM4EMEN1KMT2AUSP2
SCHEMBL12440445 0.84 USP2 (0.54) L3MBTL1KDM4EMEN1KMT2AUSP2
SCHEMBL18330504 0.81 EPHX2 (0.57) EPHX1EPHX2
SCHEMBL20061877 0.81 KDM4E (0.45) L3MBTL1KDM4EMEN1MAPTKMT2A
SCHEMBL13191363 0.81 EPHX2 (0.53) L3MBTL1KDM4EMEN1MAPTKMT2A
SCHEMBL12438989 0.81 NPSR1 (0.59) L3MBTL1MEN1KMT2AEPHX1USP2
SCHEMBL6003218 0.81 NPSR1 (0.65) L3MBTL1MEN1KMT2AEPHX1USP2
SCHEMBL14309155 0.80 NPSR1 (0.68) L3MBTL1MEN1KMT2AEPHX1USP2
SCHEMBL17730252 0.78 USP2 (0.49) L3MBTL1KDM4EMEN1KMT2AEPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160368930-A1 COMPOSITIONS AND METHODS FOR TREATING CANCER THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2016-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160368930-A1 COMPOSITIONS AND METHODS FOR TREATING CANCER KRAS, HRAS, NRAS L3MBTL1 3338/4885KDM4E 3032/4885MEN1 2804/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.